References
- Druker BJ, Talpaz M, Resta DJ, . Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031–1037.
- Druker BJ, Sawyers CL, Kantarjian H, . Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038–1042.
- Ohnishi K, Sakai F, Kudoh S, . Twenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesylate. Leukemia 2006;20:1162–1164.
- Seki N, Ito A, Watanabe K, . Irreversible imatinib-induced pneumonitis following long-term imatinib administration. Intern Med 2007;46:1941–1942.
- Bergeron A, Réa D, Levy V, . Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. Am J Respir Crit Care Med 2007;176:814–818.
- Swords R, Mahalingam D, Padmanabhan S, . Nilotinib: optimal therapy for patients with chronic myeloid leukemia and resistance or intolerance to imatinib. Drug Des Devel Ther 2009;3:89–101.